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Background: Since troponins havebecomewidely available, the roles of other less speciﬁc biomarkers formyocardial
necrosis following coronary artery bypass grafting (CABG) have been seldom studied. Aspartate aminotransferase
(AST) may not only be released from the heart but also from the liver or skeletal muscle. We assessed whether
post-operative AST levels were associated with mortality and morbidity after contemporary (CABG).
Method: Patients undergoing isolated CABG during July 2010–June 2012 at Auckland City Hospital were included
if they had a post-operative AST measurement within 48 h (n=804 of 818). The prognostic utility of 2× upper
limit of normal of AST (N90 U/L) pre-speciﬁed for adverse outcomes was assessed.
Results: Median post-operative AST level was 37 U/L (lower quartile 30, upper quartile 48). In multivariable
analysis, including baseline characteristics, AST N90 U/L was independently associated with 30-day mortality
(OR 12.0, 95% CI 2.99–47.9, P b 0.001), long-termmortality (OR 12.0, 95% CI 1.69–34.8, P b 0.001) and composite
morbidity (OR 3.31, 95% CI 1.56–7.02, P = 0.002). AST as a continuous parameter remained an independent
predictor for 30-day and long-term mortality when hs-TnT was adjusted for but not for composite morbidity.
Independent predictors of AST N90 U/L included female sex, unstable angina and operation time.
Conclusion: Increase in AST levels within 48 hours of CABGwas a strong independent predictor of 30 daymortal-
ity. Although AST increase is not speciﬁc to myocardial necrosis, it remains useful for prognosis in cardiac
surgery.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac troponins are the recommended biomarkers for diagnosing
myocardial infarction (MI), including type 5 MI, which is associated
with coronary artery bypass grafting (CABG) [1]. Over the last decade,
studies of cardiac biomarkers for type 5 MI have therefore focused on
troponins, with a paucity of literature about older biomarkers such as
aspartate aminotransferase (AST). This has occurred in part because
troponins have superior sensitivity, speciﬁcity and prognostic value
in this context [2–5]. However, one contemporary study reported
post-operative AST levels independently predicted early and late mor-
tality after CABG [6], but this ﬁnding has not been reproduced in other
recent studies [7–9]. Whether AST levels are related to post-operativeService, Auckland City Hospital,
ew Zealand. Tel.: +64 9 630
.
liability and freedom from bias
land Ltd. This is an open access article ucomplications has not been previously studied. Older studies from our
centre identiﬁed a cutpoint for AST twice the upper limit of normal
(ULN) to be associated with myocardial damage after cardiac surgery
[10,11]. We therefore assessed the prognostic utility of this cutpoint
for post-operative AST levels to predict mortality and morbidity after
CABG and compared AST with high-sensitivity troponin T (hs-TnT).2. Methods
Ethics approval was attained from the ethics committee of our
institution's research ofﬁce. The study involved patients who
underwent isolated CABG without concomitant valve surgery from
July 2010 to June 2012 at Auckland City Hospital. Patients were in-
cluded if they had AST levels measured within 48 h after CABG,
which was routinely performed in the cardiovascular intensive care
unit. Where several measurements were taken the highest level
was recorded. The normal reference range for AST is b45 U/L. This
was compared to hs-TnT levels routinely measured 12–24 h after
surgery, which has a 99% upper reference limit (URL) of 14 ng/L.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics.
AST ≤ 90
(n= 755)
AST N 90
(n= 49)
P-value
Demographics
Age, years 64.6 (10.0) 62.6 (10.0) 0.165
Female 19.2% (145) 40.8% (20) 0.001
Ethnicity 0.634
Caucasian 54.6% (412) 51.0% (25)
Maori or Paciﬁc 24.6% (186) 22.4% (11)
Other 20.8% (157) 26.5% (13)
BMI, kg/m2 29.0 (5.3) 30.3 (6.3) 0.244
Presentation
Angina CCS class IV 36.7% (277) 51.0% (25) 0.049
Dyspnoea NYHA class IV 4.0% (30) 6.1% (3) 0.446
Recent myocardial infarction within 6
weeks
49.5% (374) 51.0% (25) 0.883
Critical pre-operative state⁎ 9.4% (71) 12.2% (6) 0.457
Inpatient operation 79.3% (599) 81.6% (40) 0.855
Past Medical History
Myocardial infarction 66.0% (498) 73.% (36) 0.349
Percutaneous coronary intervention 10.7% (81) 14.3% (7) 0.475
Coronary artery bypass grafting 1.2% (9) 4.1% (2) 0.141
Congestive heart failure 5.7% (43) 2.0% (1) 0.511
Atrial ﬁbrillation 7.9% (60) 2.0% (1) 0.167
Diabetes 38.4% (290) 34.7% (17) 0.652
Diabetes on insulin 10.9% (82) 8.2% (4) 0.810
Hypercholesterolaemia 91.5% (691) 93.9% (46) 0.790
Hypertension 71.0% (536) 61.2% (30) 0.149
Current smoker 14.0% (106) 24.5% (12) 0.059
Stroke 6.5% (49) 4.1% (2) 0.762
Peripheral vascular disease 11.3% (85) 6.1% (3) 0.348
Chronic respiratory disease 17.2% (130) 10.2% (5) 0.241
Dialysis 3.2% (24) 0.0% (0) 0.391
Investigations
Left main stem N50% stenosis 43.7% (330) 46.9% (23) 0.659
Three-vessel disease 82.1% (620) 67.3% (33) 0.014
Ejection fraction 0.133
Normal (N50%) 71.4% (539) 63.3% (31)
Mild impairment (40–50%) 14.3% (108) 10.2% (5)
Moderate impairment (30–40%) 9.1% (69) 16.3% (8)
Severe impairment (b30%) 5.2% (39) 10.2% (5)
Estimated GFR (mL/min) 79.3 (28.6) 78.4 (29.5) 1.000
EuroSCORE I 4.4% (4.8%) 4.6% (6.4%) 0.539
EuroSCORE II 2.5% (2.9%) 3.2% (4.7%) 0.575
AST = aspartate aminotransferase; BMI = body mass index; CCS = Canadian Cardiovas-
cular Society Classiﬁcation;NYHA=NewYorkHeart Association Functional Classiﬁcation.
⁎ Critical pre-operative state involved patientswho required inotrope, ventilator and/or
intra-aortic balloon pump (IABP) support during the hospital admission prior to surgery.
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computerised records retrospectively.
Deﬁnitions for pre-operative characteristics are as follows. Angina
and dyspnea were graded using the Canadian Cardiovascular Society
Classiﬁcation (CCS) and the New York Heart Association Functional
Classiﬁcation (NYHA), respectively. Critical pre-operative state involved
patients who required inotrope, ventilator and/or intra-aortic balloon
pump (IABP) support during the hospital admission prior to surgery.
Hypertension referred to a previous formal diagnosis, being prescribed
medications to reduce blood pressure or any measurement of over
140/90 mmHg pre-operatively. Stroke was deﬁned as neurological
deﬁcit that persisted over 24 h as a result of disturbance of cerebral
blood supply. Peripheral vascular disease included claudication, ankle
brachial index b0.9, imaging evidence of N50% stenosis in any peripher-
al artery, a peripheral vascular intervention or amputation for arterial
insufﬁciency. Chronic respiratory diseases included a previous formal
diagnosis, use of inhaled corticosteroids for respiratory symptoms
or forced expiratory volume in 1 s (FEV1) b80% on spirometry. The
number of major coronary vessels with N50% stenosis was recorded.
Estimated glomerular ﬁltration rate (eGFR) was calculated using the
Modiﬁcation of Diet and Renal Disease equation and the last serum
creatinine measurement pre-operatively. EuroSCORE I and II were
calculated to estimate operative risk [12,13]. The type and number of
bypass grafts and duration of operation, cardiopulmonary bypass and
aortic cross-clamps were recorded.
Mortality data were obtained from New Zealand's national registry
up until 30 June 2014. Five post-operative complications as deﬁned by
the Society of Thoracic Surgeon's (STS) score and their composite
were determined, including permanent stroke (acute neurological
deﬁcit N24 h due to cerebral blood supply disturbance), renal failure
(new dialysis requirement or increase of creatinine to N4.0 mg/dL
and N3 times last pre-operative level), prolonged ventilation N24 h,
deep sternal wound infection and return to theatre for any reason
[14]. Peri-operative MI was deﬁned according to the Third Universal
Deﬁnition for type 5 MI [1], including troponin increase to more than
10 times the99th percentile URL of the assay and newsigns of infarction
on ECG, echocardiogram, coronary angiogram or magnetic resonance
imaging. The pre-speciﬁed outcomes for analyses were 30-day mortali-
ty, long-term mortality during follow-up and composite morbidity.
2.1. Statistical analyses
We pre-speciﬁed dividing patients into two groups based on a
cutpoint of 90 U/L, i.e. twice the ULN, for analyses. Mann–Whitney
U test and Fisher's exact test were used for univariate analyses for
continuous (presented as mean/standard deviation) and categorical
variables (percentage/frequency), respectively. Kaplan–Meier curves
and log-rank (Mantel–Cox) test was used for univariate longitudinal
analyses. Receiver-operative characteristics analysis was used to
calculate c-statistic and 95% conﬁdence interval (95% CI). Multivariable
analyses incorporated variables with P b 0.10 in univariate analyses,
using logistic regression to calculate odds ratios (OR) for cross-
sectional outcomes andCox proportional hazards regression used to cal-
culate hazards ratios (HR) for mortality. AST and hs-TnT as continuous
parameters, and separately AST N90 U/L were included in the multivar-
iable models for outcomes. All tests were two-tailed with signiﬁcance
level set at 0.05. Statistical software used were SPSS (Version 17.0,
SPSS Inc., Chicago, IL, USA) and Prism (Version 5, GraphPad Software,
San Diego, CA, USA).
3. Results
A total of 818 patients underwent isolated CABG during the two-
year study period, of which 804 had post-operative AST measurements
within 48 h included in the study, 555 (69.0%) of whom had AST in thenormal range b45 U/L. Median post-operative AST levels was 37 U/L
(lower quartile 30, upper quartile 48).
Table 1 presents the baseline characteristics for subjects with post-
operative AST≤ and N90 U/L. Those with AST N90 U/L (n = 49, 6.1%)
had a higher proportion of women (40.8% vs. 19.2%, P = 0.001)
and higher prevalence of CCS class IV angina (51.0% vs. 36.7%, P =
0.049).
Operative and post-operative data are shown in Table 2. AST N90U/L
was associatedwith longer operation time (229 vs. 215min, P=0.037).
In univariate analyses for outcomes, AST N90 U/L was associated with
30-daymortality (OR 12.1, 95% CI 3.70–39.8, P b 0.001), compositemor-
bidity (OR 3.51, 95% CI 1.92–6.40, P b 0.001), ventilation N 24 h (OR 3.58,
95% CI 1.90–6.77, P b 0.001), peri-operative MI (OR 2.78, 95% CI 1.28–
6.02, P = 0.01) and new atrial ﬁbrillation (OR 1.96, 95% CI 1.06–3.62,
P= 0.032).
Fig. 1 illustrates survival over amean follow-up of 2.8±0.6 years. Pa-
tients with AST N90 U/L had signiﬁcantly greater long-term mortality
(HR 19.8, 95% CI 3.36–117, P b 0.001). One-year survival was 87.3% for
patients with AST N90 U/L compared to 98.0% for patients AST b90 U/L.
Most of the difference was within the ﬁrst month.
Table 2
Operative variables and outcomes.
AST ≤ 90
(n= 755)
AST N 90
(n= 49)
P-value
Operation Details
Off-pump 2.8% (21) 2.0% (1) 1.000
Number of bypassed vessels 3.3 (0.8) 3.1 (0.7) 0.134
Left internal mammary artery graft 98.1% (741) 93.9% (46) 0.079
Right internal mammary artery graft 5.8% (44) 10.2% (5) 0.213
Radial artery graft 22,6% (171) 34.7% (17) 0.080
Saphenous vein grafts 93.9% (709) 89.8% (44) 0.229
Operation time (minutes) 215 (220) 229 (247) 0.037
Cardiopulmonary bypass time (minutes) 91 (25) 99 (44) 0.609
Cross-clamp time (minutes) 59 (20) 59 (29) 0.362
Post-operative outcomes
Composite morbidity 16.4% (124) 40.8% (20) b0.001
Stroke 0.9% (7) 4.1% (2) 0.100
Renal failure 2.1% (16) 4.1% (2) 0.301
Ventilation N24 h 11.9% (90) 32.7% (16) b0.001
Deep sternal wound infection 0.4% (3) 0.0% (0) 1.000
Return to theatre 4.6% (35) 10.2% (5) 0.089
New atrial ﬁbrillation 21.3% (161) 34.7% (17) 0.034
Perioperative myocardial infarction 12.2% (66) 27.8% (10) 0.018
hs-TnT N140 ng/L 86.5% (475) 86.1% (31) 1.000
New ECG and/or echocardiographic changes 12.6% (94) 25.0% (12) 0.026
Operation to discharge (days) 8.1 (5.8) 8.5 (4.3) 0.073
Total mortality 2.3% (17) 12.2% (6) 0.002
Mortality at 30 days 0.9% (7) 10.2% (5) b0.001
Mortality after 30 days 1.3% (10) 2.0% (1) 0.502
AST = aspartate aminotransferase; hs-TnT = high-sensitivity troponin T.
Table 3
Receiver-operative characteristics analyses.
Outcome AST C-statistic Hs-TnT C-statistic
30-day mortality 0.762 (0.609–0.915) 0.649 (0.452–0.845)
Long-term mortality 0.580 (0.491–0.670) 0.637 (0.507–0.768)
Composite morbidity 0.573 (0.518–0.628) 0.708 (0.656–0.760)
Stroke 0.615 (0.464–0.766) 0.635 (0.455–0.814)
Renal failure 0.445 (0.313–0.576) 0.659 (0.506–0.811)
Ventilation N24 h 0.615 (0.555–0.676) 0.732 (0.675–0.788)
Deep sternal wound infection 0.584 (0.170–0.999) 0.694 (0.232–1.000)
Return to theatre 0.479 (0.380–0.578) 0.644 (0.549–0.739)
Perioperative myocardial infarction 0.594 (0.524–0.664) 0.575 (0.505–0.644)
All ﬁgures are c-statistic with 95% CI.
Bolded = signiﬁcant ﬁndings.
AST = aspartate aminotransferase; hs-TnT = high-sensitivity troponin T.
Table 4
Multivariable analyses.
AST N90 U/L Odds ratio 95% Conﬁdence
interval
P-value
Female 2.67 1.44–4.96 0.002
CCS Class IV 1.71 1.04–2.81 0.023
Left internal mammary graft 0.338 0.173–0.662 0.002
Operation time (per 10 min) 1.18 1.06–1.31 0.001
30-day mortality Odds ratio 95% Conﬁdence
interval
P-value
Female 4.41 1.25–15.6 0.021
Maori/Paciﬁc ethnicity 6.47 1.70–24.7 0.006
NYHA Class IV 11.2 2.71–45.7 0.001
AST N90 U/L 12.0 2.99–47.9 b0.001
AST (per 10 U/L increase) 1.14 1.04–1.24 0.004
hs-TnT (per 100 ng/L increase) 1.02 0.978–1.05 0.429
Long-term mortality Hazards ratio 95% Conﬁdence
interval
P-value
Peripheral vascular disease 3.24 1.14–9.19 0.027
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are listed in Table 3. Post-operative AST levels were associated with
30-day mortality (c-statistic 0.762, 95% CI 0.609–0.915, P = 0.002),
composite morbidity (c-statistic 0.573), ventilation N 24 h (c-statistic
0.615) and peri-operative MI (c-statistic 0.594). Hs-TnT was associated
with long-term mortality (c = 0.637), composite morbidity (c =
0.708), renal failure (c = 0.659), ventilation N24 h (c = 0.732), return
to theatre (c = 0.644) and perioperative MI (c = 0.575).
Table 4 shows the variables with P b 0.10 in multivariable analyses.
Female sex, CCS Class IV angina and operation time were independent
predictors of AST N90 U/L. AST N90 U/L was independently associated
with 30-day mortality (OR 12.0, 95% CI 2.99–47.9, P b 0.001), long-
term mortality (OR 12.0, 95% CI 1.69–34.8, P b 0.001) and composite
morbidity (OR 3.31, 95% CI 1.56–7.02, P=0.002). If post-operative com-
plications was introduced into the model, AST N90 U/L remained an0.0 0.5 1.0 1.5 2.0 2.5 3.0
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Fig. 1. Kaplan–Meier survival curve by AST group.independent predictor of 30-day mortality (OR 7.61, 95% CI 1.69–34.8,
P= 0.008).
Post-operative AST, as a continuous parameter when hs-TnT was
adjusted for, independently predicted 30-day mortality (OR 1.14, 95%
CI 1.04–1.25, P = 0.004) and long-term mortality (HR 1.08, 95% CI
1.01–1.16, P = 0.031) but not composite morbidity (OR 1.03, 95% CI
0.962–1.10, P = 0.409). Hs-TnT as a continuous parameter predictedLeft internal mammary graft 0.171 0.039–0.753 0.020
Ventilation N 24 h 3.39 1.30–8.84 0.0.012
Return to theatre 4.24 1.48–12.1 0.007
AST N90 U/L 4.07 1.52–10.9 0.005
AST (per 10 U/L increase) 1.08 1.00–1.15 0.037
hs-TnT (per 100 ng/L increase) 1.00 0.970–1.03 0.987
Composite morbidity Odds ratio 95% Conﬁdence
interval
P-value
CCS Class IV 1.48 0.949–2.31 0.084
Critical pre-operative state⁎ 2.29 1.24–4.22 0.008
Diabetes on insulin 2.11 1.15–3.86 0.015
Current smoker 2.02 1.15–3.54 0.008
Previous coronary artery
bypass grafting
4.44 1.09–18.1 0.038
Left main stem N50% stenosis 1.62 1.05–2.50 0.029
Ejection fraction impaired b40% 3.30 2.00–5.47 b0.001
eGFR (per mL/min) 0.991 0.983–0.998 0.019
AST N90 U/L 3.31 1.56–7.02 0.002
AST (per 10 U/L increase) 1.03 0.962–1.10 0.409
hs-TnT (per 100 ng/L increase) 1.09 1.05–1.13 b0.001
AST= aspartate aminotransferase; CCS= Canadian Cardiovascular Society Classiﬁcation;
eGFR = Estimated glomerular ﬁltration rate; hs-TnT = high-sensitivity troponin
T; NYHA = New York Heart Association Functional Classiﬁcation.
⁎ Critical pre-operative state involved patientswho required inotrope, ventilator and/or
intra-aortic balloon pump (IABP) support during the hospital admission prior to surgery.
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or long-term mortality (P= 0.987).4. Discussion
The novel ﬁnding of our study is that elevated AST levels indepen-
dently predicts 30-day mortality and long-term mortality after isolated
CABG even when adjusted for hs-troponin. It was also independently
associated with composite morbidity after adjustment for baseline
variables.
AST is an enzyme that catalyses aspartate and α-ketoglutarate to
oxaloacetate and glutamate, and is mainly found in the liver, followed
by the heart and other organs including skeletal muscle, brain and
kidneys. AST peaks around 24–36 h post-operatively after CABG, and re-
mains elevated for 3–5 days [15,16]. The wide tissue distribution
impairs its speciﬁcity for myocardial damage and therefore MI diagno-
sis. However, AST might be a prognostic indicator in cardiac surgery
because non-cardiac sources of AST rise such as liver or skeletal muscle
can also reﬂect impaired cardiac function, ischaemia and decreased tis-
sue perfusion. We routinely measure AST after cardiac surgery because
of earlier work published from our centre showing AST's correlation
with myocardial damage and prognosis in this context [10,11].
A few studies have found AST to be independently associated
with mortality after CABG [6,17]. However, other smaller and under-
powered studies did not ﬁnd an independent association [7–9]. Early
studies showed that AST levels remained normal in the majority of
patients after CABG [18,19]. One study found 71.8% of patients having
AST b50 U/L post-operatively, similar to the 68.9% of patients having
normal AST b45 U/L in our study [6].
Although AST N90 U/L predicted both 30-day and long-termmortal-
ity in our study, themain difference inmortalitywas in the ﬁrst 30 days,
whereas late mortality was not signiﬁcantly different. Similar results
have been reported in other studies [6,17]. This was true even after
adjusting for post-operative complications including ventilation N24 h
and return to theatre, as well as hs-TnT, suggesting its prognostic
value for early mortality has a different pathophysiology.
The optimal cutpoint for AST rise for predictingmortality after CABG
would be expected to differ from that for hs-troponin. The recent
third universal deﬁnition for type 5 MI, which involves dual criteria of
elevated biomarkers, preferably troponin, with new signs of infarction
on electrocardiogram, echocardiogram, coronary angiogram or cardiac
magnetic resonance imaging and arbitrarily set the biomarker threshold
at 10 times 99th percentile URL [1]. This threshold is supported by a
subsequent study using high-sensitivity troponin T of N140 ng/L, i.e.,
10 times 99th percentile URL with ECG and/or echocardiographic
criteria [20]. Other studies of isolated troponin rise in CABG have
found much higher optimal cutpoints of 50–160 times [21,22]. Our
study's cutpoint of AST N90 U/L is 2 times the ULN and independently
predicted 30-day and long-termmortality. Other studies have reported
lower thresholds of 3–6 times ULN for AST [6,7,17].
Our results also show that AST independently predicted compos-
ite morbidity in our study although not after hs-TnT adjustment.
AST N90 U/L was also associated with higher rates of ventilation
N24 h, new atrial ﬁbrillation and MI.4.1. Limitations
This is a single-centre retrospective study. We did not have serial
AST data for a signiﬁcant proportion of patients to assess the dynamic
proﬁle of post-operative AST levels, and did not measure AST pre-
operatively. Other liver enzymes were not routinely measured for
assessment of liver damage causing the elevation of AST. Duration of
follow-up was short given that this was a contemporary cohort, and
other outcomes during follow-up were not obtained.5. Conclusion
Post-operative AST levels predict mortality and morbidity after
CABG. AST is a useful prognostic biomarker for adverse outcomes after
CABG even though it is not speciﬁc for myocardial damage.
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